

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA ISOTOPE & RADIATION CORPORATION

中國同輻股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1763)

VOLUNTARY ANNOUNCEMENT BNCT BORON DRUG IND APPLICATION SUBMITTED BY ZHONGHE HEADWAY, A SUBSIDIARY OF CIRC

This announcement is voluntarily made by China Isotope & Radiation Corporation (“**CIRC**” or the “**Company**”) to keep its shareholders and potential investors informed of the latest business developments of the Company.

The board of directors of the Company is pleased to announce that recently, according to the information displayed on the official website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), “Bromalin (^{10}B) for Injection” submitted by the Company’s subsidiary, Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd. (“**Zhonghe Headway**”), has been officially accepted by the CDE of the NMPA, with the acceptance number CXHL2501079.

Zhonghe Headway’s investigational “Borofalan (^{10}B) for Injection” demonstrates significant clinical advantages for tumors exhibiting resistance to radiotherapy and chemotherapy, recurrent, refractory, invasive, mid-to-late stage, or locally metastatic characteristics. With a short treatment course (requiring only 1-2 sessions), low toxicity and side effects, and integrated diagnosis and treatment, it represents the development direction and cutting-edge innovation of modern precision oncology, offering patients a novel therapeutic option while driving innovation and breakthroughs in the field of tumor treatment.

The submission of the IND application for Zhonghe Headway’s BNCT boron drug marks a breakthrough achievement in China’s domestically developed BNCT technology within the field of collaborative drug-device research and development, officially inaugurating a new phase of clinical translation, injecting fresh nuclear scientific and technological momentum into precision tumor treatment under the “Healthy China” strategy while contributing the “Chinese Solution” to global tumor treatment.

By order of the Board
China Isotope & Radiation Corporation
Xiao Yafei
Chairman

Beijing, the PRC, 17 October 2025

As at the date of this announcement, the Board comprises Mr. Xiao Yafei, Mr. Zhang Junqi, Ms. Huo Yingying and Ms. Ma Xiaoyu as executive Directors; Mr. Chen Zan, Mr. Ding Jianmin and Ms. Chang Jinyu as non-executive Directors; and Mr. Poon Chiu Kwok, Ms. Chen Jingshan, Mr. Lu Chuang and Mr. An Rui as independent non-executive Directors.